FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2484493808> ?p ?o ?g. }

• W2484493808 abstract "Abstract Sensitization of leukemic cells with GM-CSF may enhance the cytotoxicity of chemotherapy in younger adults with newly diagnosed AML. In a multicenter randomized trial, 259 patients (median age, 27 years; 15–50) were randomized at baseline to receive a timed sequential induction regimen (DNR 80mg/m2/d d1-3, AraC 500mg/m2/d d1-3 and 500mg/m2/12h d8-10, Mitox 12mg/m2/d d8-9) either without (135 patients) or with GM-CSF (124 patients) administered i.v. at 5μg/kg/d from day 1 to day 10. Patients reaching CR (eventually after salvage therapy combining AraC 3g/m2/12h d1,3,5,7 and Amsa 100mg/m2/d d1-3) and not eligible for allogeneic transplantation in CR1 were then randomized to compare the ALFA-9000 consolidation (Mitox 12mg/m2/d d1-3, VP16 200mg/m2/d d8-10, AraC 500mg/m2/d d1-3,8-10) (Castaigne et al., Blood 2004) to the CALGB postremission chemotherapy, which includes 4 cycles of HD-AraC (3g/m2/12h d1,3,5) followed by 4 additional DNR/AraC courses (Mayer et al, N Engl J Med 1994). Patients initially randomized in the GM-CSF arm received GM-CSF concurrently with chemotherapy during all cycles of consolidation therapy. The effects of GM-CSF on EFS were assessed in the entire cohort and according to distinct prognostic subgroups. After induction therapy, the proportions of CR were not significantly different in the two groups (91% with GM-CSF vs 87% without). After a median follow-up of 3 years, patients receiving GM-CSF had a higher rate of EFS than those who did not receive GM-CSF (3-year EFS, 42% vs 34%, p = 0.06). GM-CSF did not significantly improve OS. Patients with intermediate risk cytogenetics benefited from GM-CSF therapy (3-year EFS, 50% vs 35%, p = 0.05), while GM-CSF did not improve the outcome in the subgroups with favorable (p = 0.8) or unfavorable cytogenetics (p = 0.3). The benefit of GM-CSF in patients with intermediate karyotype was in part related to a lower rate of relapse (29% vs 47% at 3 years, p = 0.05) and a lower TRM (19% vs 23% at 3 years). Patients with abnormal intermediate karyotype benefited more of GM-CSF therapy (3-year EFS, 55% vs 19%, p = 0.03) than those with normal karyotype (3-year EFS, 47% vs 42%, p = 0.4). However, GM-CSF did not significantly improve OS in both groups. The effect of GM-CSF in the intermediate cytogenetic group was increased when considering only patients following the second randomization (consolidation chemotherapy ± GM-CSF) (3-year EFS, 49% vs 31%, p = 0.03; 3-year OS, 65% vs 43%, p = 0.05). GM-CSF also influenced favorably the intermediate group when considering a prognostic classification based on cytogenetics and the number of chemotherapy courses required for achieving CR (Wheatley et al., Br J Haematol 1999) (3-year EFS, 50% vs 34%, p = 0.04; 3-year OS, 63% vs 44%, p = 0.04). We confirmed here that sensitization of leukemic cells with hematopoietic growth factors is a clinically means of enhancing the efficacy of chemotherapy in younger adult patients with intermediate risk AML." @default.
• W2484493808 created "2016-08-23" @default.
• W2484493808 creator A5000000264 @default.
• W2484493808 creator A5000436961 @default.
• W2484493808 creator A5002884935 @default.
• W2484493808 creator A5010517016 @default.
• W2484493808 creator A5014838075 @default.
• W2484493808 creator A5017435311 @default.
• W2484493808 creator A5018416096 @default.
• W2484493808 creator A5028365885 @default.
• W2484493808 creator A5028508696 @default.
• W2484493808 creator A5030703425 @default.
• W2484493808 creator A5034726747 @default.
• W2484493808 creator A5046391226 @default.
• W2484493808 creator A5050799774 @default.
• W2484493808 creator A5054745373 @default.
• W2484493808 creator A5057037979 @default.
• W2484493808 creator A5058825074 @default.
• W2484493808 creator A5064103067 @default.
• W2484493808 creator A5072027146 @default.
• W2484493808 creator A5072721892 @default.
• W2484493808 creator A5087870886 @default.
• W2484493808 creator A5090488919 @default.
• W2484493808 date "2005-11-16" @default.
• W2484493808 modified "2023-10-14" @default.
• W2484493808 title "Effect of Priming with Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Younger Adults with Newly Diagnosed Acute Myeloid Leukemia (AML): A Trial by the Acute Leukemia French Association (ALFA) Group." @default.
• W2484493808 doi "https://doi.org/10.1182/blood.v106.11.1862.1862" @default.
• W2484493808 hasPublicationYear "2005" @default.
• W2484493808 type Work @default.
• W2484493808 sameAs 2484493808 @default.
• W2484493808 citedByCount "0" @default.
• W2484493808 crossrefType "journal-article" @default.
• W2484493808 hasAuthorship W2484493808A5000000264 @default.
• W2484493808 hasAuthorship W2484493808A5000436961 @default.
• W2484493808 hasAuthorship W2484493808A5002884935 @default.
• W2484493808 hasAuthorship W2484493808A5010517016 @default.
• W2484493808 hasAuthorship W2484493808A5014838075 @default.
• W2484493808 hasAuthorship W2484493808A5017435311 @default.
• W2484493808 hasAuthorship W2484493808A5018416096 @default.
• W2484493808 hasAuthorship W2484493808A5028365885 @default.
• W2484493808 hasAuthorship W2484493808A5028508696 @default.
• W2484493808 hasAuthorship W2484493808A5030703425 @default.
• W2484493808 hasAuthorship W2484493808A5034726747 @default.
• W2484493808 hasAuthorship W2484493808A5046391226 @default.
• W2484493808 hasAuthorship W2484493808A5050799774 @default.
• W2484493808 hasAuthorship W2484493808A5054745373 @default.
• W2484493808 hasAuthorship W2484493808A5057037979 @default.
• W2484493808 hasAuthorship W2484493808A5058825074 @default.
• W2484493808 hasAuthorship W2484493808A5064103067 @default.
• W2484493808 hasAuthorship W2484493808A5072027146 @default.
• W2484493808 hasAuthorship W2484493808A5072721892 @default.
• W2484493808 hasAuthorship W2484493808A5087870886 @default.
• W2484493808 hasAuthorship W2484493808A5090488919 @default.
• W2484493808 hasConcept C126322002 @default.
• W2484493808 hasConcept C141071460 @default.
• W2484493808 hasConcept C143998085 @default.
• W2484493808 hasConcept C168563851 @default.
• W2484493808 hasConcept C2776611710 @default.
• W2484493808 hasConcept C2776694085 @default.
• W2484493808 hasConcept C2778041864 @default.
• W2484493808 hasConcept C2778119113 @default.
• W2484493808 hasConcept C2778336483 @default.
• W2484493808 hasConcept C2778729363 @default.
• W2484493808 hasConcept C2781413609 @default.
• W2484493808 hasConcept C2911091166 @default.
• W2484493808 hasConcept C71924100 @default.
• W2484493808 hasConcept C90924648 @default.
• W2484493808 hasConceptScore W2484493808C126322002 @default.
• W2484493808 hasConceptScore W2484493808C141071460 @default.
• W2484493808 hasConceptScore W2484493808C143998085 @default.
• W2484493808 hasConceptScore W2484493808C168563851 @default.
• W2484493808 hasConceptScore W2484493808C2776611710 @default.
• W2484493808 hasConceptScore W2484493808C2776694085 @default.
• W2484493808 hasConceptScore W2484493808C2778041864 @default.
• W2484493808 hasConceptScore W2484493808C2778119113 @default.
• W2484493808 hasConceptScore W2484493808C2778336483 @default.
• W2484493808 hasConceptScore W2484493808C2778729363 @default.
• W2484493808 hasConceptScore W2484493808C2781413609 @default.
• W2484493808 hasConceptScore W2484493808C2911091166 @default.
• W2484493808 hasConceptScore W2484493808C71924100 @default.
• W2484493808 hasConceptScore W2484493808C90924648 @default.
• W2484493808 hasLocation W24844938081 @default.
• W2484493808 hasOpenAccess W2484493808 @default.
• W2484493808 hasPrimaryLocation W24844938081 @default.
• W2484493808 hasRelatedWork W1509346046 @default.
• W2484493808 hasRelatedWork W2138205116 @default.
• W2484493808 hasRelatedWork W2294565310 @default.
• W2484493808 hasRelatedWork W2377520785 @default.
• W2484493808 hasRelatedWork W2386236634 @default.
• W2484493808 hasRelatedWork W2592110561 @default.
• W2484493808 hasRelatedWork W3043536668 @default.
• W2484493808 hasRelatedWork W3043781363 @default.
• W2484493808 hasRelatedWork W3213132589 @default.
• W2484493808 hasRelatedWork W4253125675 @default.
• W2484493808 isParatext "false" @default.
• W2484493808 isRetracted "false" @default.
• W2484493808 magId "2484493808" @default.
• W2484493808 workType "article" @default.